(Q37775029)

23 August 2017

1 reference

title

Novel drugs to treat hemophilia (English)

1 reference

23 August 2017

0 references

Leonard A Valentino

1

1 reference

23 August 2017

Yousef Ismael

series ordinal

2

1 reference

23 August 2017

Michele Grygotis

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

24 July 2010

1 reference

Expert Opinion on Emerging Drugs

23 August 2017

published in

1 reference

23 August 2017

volume

15

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

597-613

1 reference

Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Musculoskeletal complications of haemophilia: the joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Pathogenesis of haemophilic arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Intracranial bleeding in haemophilia beyond the neonatal period--the role of CT imaging in suspected intracranial bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Successful control of bleeding during supracondylar amputation caused by severe compartment syndrome in patient with haemophilia A and high titre of inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Disseminated intravascular coagulation and myocardial infarction in a haemophilia B patient during therapy with prothrombin complex concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Therapeutic decision-making in inhibitor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Inhibitors: resolving diagnostic and therapeutic dilemmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Genetic risk factors for inhibitors to factors VIII and IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

21 January 2018

Overview of inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Inhibitor antibodies to factor VIII and factor IX: management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Immune tolerance therapy for haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Factor IX inhibitors and anaphylaxis in hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

International immune tolerance registry, 1997 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Articular status of haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Haemophilia prophylaxis in young patients--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Long-term outcome of individualized prophylactic treatment of children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Intracranial haemorrhage among a population of haemophilic patients in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

The overall effectiveness of prophylaxis in severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Effects of secondary prophylaxis started in adolescent and adult haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

When to start and when to stop primary prophylaxis in patients with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Controversies regarding the prophylactic management of adults with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Practice patterns in haemophilia A therapy – a survey of treatment centres in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Practice patterns in haemophilia A therapy -- global progress towards optimal care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Surveillance of infectious complications associated with central venous access devices in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Consensus recommendations for use of central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Arteriovenous fistula for long-term venous access for boys with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

The impact of prophyactic treatment on children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Recommendations on biosimilar low-molecular-weight heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Cell biology of von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

The turnover rate of serum albumin in man as measured by I131-tagged albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Prolonged activity of factor IX as a monomeric Fc fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Aptamer therapeutics advance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Aptamers and aptamer targeted delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Transgenic pigs produce functional human factor VIII in milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2010.506871

10.1517/14728214.2010.506871

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference